Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (trading symbol: NAOV) on August 22, 2023. The report details a material definitive agreement entered into on August 22, 2023, effective as of August 11, 2023. The company is incorporated in Delaware and its common stock is listed on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding a contractual agreement and does not contain financial statements, revenue figures, profit data, cash flow metrics, debt levels, or liquidity ratios. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The primary material change reported is the execution of a second amendment to the Amended and Restated Distribution Agreement with Ultra Pain Products Inc. ("UPPI"). Key terms include:
- Exclusive Distribution: UPPI remains the exclusive distributor for PainShield and PainShield Plus devices within the U.S. Durable Medical Equipment sector.
- Order Guarantees: The agreement mandates an immediate re-stocking order and establishes minimum purchase guarantees through the end of 2023.
- Term Duration: The amendment term is 12 months or until the Centers for Medicare and Medicaid Services (CMS) assigns a reimbursement value to the PainShield product, whichever occurs first.
- Future Negotiations: Upon expiration, parties agreed to negotiate in good faith for a new distribution agreement.
Guidance, Outlook, and Risks
Outlook: The agreement secures distribution channels and inventory commitments for the remainder of 2023. The term of the agreement is contingent on regulatory action by CMS regarding reimbursement values.
Risks and Contingencies: The duration of the current agreement is capped by the potential assignment of a reimbursement value by CMS. If CMS assigns a value before the 12-month term expires, the agreement may conclude earlier, necessitating immediate renegotiation.
Investor Verification Checklist
- Verify the specific volume of the "immediate re-stocking order" and the dollar value of the minimum purchase guarantees through 2023.
- Monitor CMS updates regarding the reimbursement status of the PainShield product, as this triggers the early termination of the agreement term.
- Confirm the status of the press release dated August 23, 2023 (Exhibit 99.1) for additional market commentary.
- Review the original December 10, 2020 Distribution Agreement to understand the baseline terms prior to this amendment.